جستجوی مقالات مرتبط با کلیدواژه "هزینه های مستقیم درمان" در نشریات گروه "پزشکی"

Knowing the main components of treatment costs can help policy makers and decision makers in controlling treatment costs and reviewing insurance coverage plans. The purpose of this study was to analyze the cost of treating patients with covid-19.

This study was a descriptive economic evaluation study that was conducted cross-sectional on 28,997 corona patients hospitalized in a large medical center in Tehran. The data required for the study included the cost components of direct treatment in corona patients (drugs, laboratory tests, diagnostic imaging and hoteling) and socio-economic variables (age, gender, type of insurance coverage, marital status) Hospital accounting was collected. The analysis of treatment costs and its components was done using descriptive statistics and with the help of central and dispersion indicators (mean and standard deviation) and using STATA software.

The average cost of treatment for each patient with covid was 121 million rials. More than half (50.75%) of the treatment costs of Covid-19 patients were related to hoteling and the patient's stay in the hospital. After that, drug costs (28.42%), paraclinical costs (8.65%) and hemoperfusion (5.4%) had the largest share in the cost of treating these patients, respectively. On average, 33.6% of the costs were paid by the patient and 66.4% by insurance organizations.

In order to control and reduce the costs of Covid-19 patients, strategies such as eliminating unnecessary hospitalizations, reducing the length of stay of patients, and developing home care services should be taken into consideration by policymakers.

Psoriasis is a systemic and non-transmissible chronic inflammatory autoimmune skin disease that about 2-3% of Iranians suffer from it. Cost of management and budgeting and planning for the treatment of patients with psoriasis requires accurate information. The present study estimates the direct and indirect costs for one-year treatment of patients admitted in Razi Dermatology Hospital.

In this descriptive-analytical study, treatment costs of 170 patients with psoriasis, including direct (medical and non-medical) and indirect costs were evaluated by census method and using a researcher-made checklist, from October 2017 to October 2018. The fee was collected through reviewing patients' bills in the hospital information system and through telephone interviews with patients.

The average cost of one year was 9037480 Tomans ($ 758), of which direct cost of treatment was 90.22% (8178681 Tomans) and indirect cost of treatment was 9.78% (858799 Tomans). The highest cost of treatment was related to pharmaceutical services with 5825233 Tomans. Also, the total direct medical cost was equal to 7069890 Tomans, of which 62% was the insurance share and 38% was the patient share. The findings showed that injecting biological drugs and accommodation had a significant effect on the direct cost of treatment. Supplementary insurance and accommodation variables also affect out-of-pocket costs.

Drugs made up most of the costs. The high price of biologics and the low coverage of these drugs by insurance companies have caused many economic problems for these patients. According to the findings of this study, it seems necessary to review the more complete insurance coverage of these drugs as well as the use of charitable assistance to cover part of the cost for treatment.